Episode 21 - Conversations in Relapsed/Refractory Multiple Myeloma: Strategies to Effectively Introduce, Optimize, and Sequence Bispecific Antibody Therapy - Part 3: Introducing, Optimizing, and Sequencing Bispecific Antibodies

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC/ACPE podcasts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.Launch Date: May 2, 2024Release Date: May 2, 2024Expiration Date: April 30, 2025FACULTY BIOJesús G. Berdeja, MDDirector of Multiple Myeloma ResearchThe Greco-Hainsworth Tennessee Oncology Centers for ResearchJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversitySaad Usmani, MDChief, Myeloma ServiceMemorial Sloan Kettering Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-relapsedrefractory-multiple-myeloma-strategies-to-effectively-introduce-optimize-and-sequence-bispecific-antibody-therapy-8